==== Front J CancerJ CancerjcaJournal of Cancer1837-9664Ivyspring International Publisher Sydney 10.7150/jca.25973jcav09p2751Research PaperXPA gene polymorphisms and risk of neuroblastoma in Chinese children: a two-center case-control study Tao Jing 1#Zhuo Zhen-Jian 2#Su Meng 3Yan Lizhao 3He Jing 4✉Zhang Jiao 3✉1 Department of Pathology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450053, Henan, China2 School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China3 Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China4 Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China✉ Corresponding authors: Jiao Zhang, Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou 450052, Henan, China, Tel./Fax: (+86- 0371) 66279071, Email: zhangjiaomail@126.com; or Jing He, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, China, Tel./Fax: (+86-020) 38076560, Email: hejing@gwcmc.org.# These authors contributed equally to this work. Competing Interests: The authors have declared that no competing interest exists. 2018 1 7 2018 9 15 2751 2756 9 3 2018 9 6 2018 © Ivyspring International Publisher2018This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.Neuroblastoma is a malignant tumor arising from the developing sympathetic nervous system, which mainly affects children. Variations in XPA gene have been shown to confer cancer susceptibility. However, no investigation has been reported regarding the association between XPA polymorphisms and neuroblastoma risk. This study was conducted to measure the association of XPA polymorphisms with neuroblastoma susceptibility in Chinese children. In this hospital-based case-control study with 393 cases and 812 controls, we genotyped two polymorphisms (rs1800975 T>C, and rs3176752 G>T) in XPA gene to access their contributions to neuroblastoma risk by TaqMan methods. The strength of the association with neuroblastoma risk was estimated by odds ratios (ORs) and 95% confidence intervals (CIs). No single polymorphism was found to predispose to neuroblastoma susceptibility. When risk genotypes were combined, we found that carriers of 1-2 risk genotypes had significantly increased neuroblastoma risk (adjusted OR=1.28; 95% CI=1.001-1.64, P=0.049), when compared to non-carriers. Stratification analysis by age, gender, sites of origin and clinical stages failed to show any significant association. Our study provides cues that XPA gene polymorphisms may exert a weak effect in neuroblastoma risk. This finding needs further validations by larger sample size studies. neuroblastomaXPApolymorphismsusceptibility ==== Body Introduction Neuroblastoma, a solid cancer originating from neural crest progenitor cells, is one of the most common tumors in children 1. The median age at diagnosis of neuroblastoma is about 17 months. Neuroblastoma accounts for approximately 10% of all pediatric cancers, yet its proportion of all pediatric cancer mortality accounts for up to 15% 2. The incidence rate of neuroblastoma in China is about 1 out of 13,000 3. In contrast, America witnesses is much higher, nearly 1 out of 7000 4. Neuroblastoma is characterized by high heterogeneity in its clinical phenotypes and symptoms 5. Based on the clinical, pathologic, and prognostic factors, neuroblastoma cases are generally classified into low-, intermediate-, high- and ultra-high-risk groups 6. Among them, high- and ultra-high-risk groups constitute around 50% of all cases. The outcome of these high- and ultra-high-risk groups are poor, with less than 40% cases achieving long-term survival 1. Poor prognosis was mainly attributed to the widespread metastasis of tumor at the time of diagnosis 7, 8. Approximately 1-2% of all cases of neuroblastoma are familial 5. Using large-scale genetic linkage studies, several candidate predisposition chromosomal regions (2p, 12p, and 16p) have been found to associate with familial neuroblastoma risk 9, 10. These findings further led to the discovery of certain gene mutations. Most of the familial cases have highly penetrant mutations in PHOX2B 11, 12 and ALK gene 13. However, the underlying etiology of sporadic neuroblastoma, the most common form, remains to be elucidated. Although environmental factors such as the conception and pregnancy exposures are potential risk of sporadic neuroblastoma, direct link between has not yet been established 14, 15. Expanding body of evidence has suggested that genetic factors and genetic-environmental interactions could contribute to the susceptibility of neuroblastoma. Recent genome-wide association studies (GWASs) have identified several neuroblastoma susceptibility loci, including single nucleotide polymorphisms (SNPs) in HACE1, LIN28B, BARD1, CASC15, TP53, and LMO1 16-21. The association of neuroblastoma risk with LMO1, BARD1, LIN28B, and TP53 polymorphisms have been confirmed in many replication case-control studies 22-26. Another powerful way to investigate the role of gene polymorphisms in cancer risk is to analyze the genetic linkage between potential functional SNPs in core genes and cancer susceptibility. This method could overcome the limitation of GWAS, as most of the GWAS-identified SNPs only have modest risk effects due to the adoption of restricted P-value (1 × 105) 27. Therefore, additional neuroblastoma susceptibility loci or gene polymorphisms are warranted to be identified. The stability of cellular functions and genomic integrity is primarily maintained by DNA repair systems 28. Among the various DNA repair systems, the nucleotide excision repair (NER) pathway is responsible for excising bulky DNA lesions 29. A myriad of evidences have proven that defects in NER pathway might weaken the DNA repair capacity and thus predispose to cancer risks 30. The NER process mainly consists of four steps: damage recognition, unwinding of the DNA, removal of the damage, and ligation 31, 32. Eight critical genes (XPA-XPG and ERCC1) participate in the repair process and coordinately maintain genomic integrity 33. XPA (xeroderma pigmentosum complementary group A) gene encodes a zinc finger DNA binding protein. This DNA binding-protein, XPA, is essential in organizing the DNA damage site and then functioning as a scaffold to excise lesions 34, 35. Owing to the important role of XPA protein in NER pathway, the association between XPA polymorphisms and cancer risk remains a hot spot of research. By now, several epidemiological studies have been performed to determine of the association with the risk of cancer, including colorectal cancer 36, laryngeal cancer 37, lung cancer 38, and B-cell lymphoma 39. Because of the universal importance of XPA in cancer, we conducted a case-control study to determine whether the SNPs in XPA gene could predispose to neuroblastoma in Chinese population. Materials and methods Study subjects Totally, 393 cases with neuroblastoma and 812 healthy controls were recruited in this hospital-based epidemiological study 40-42. To be specific, 275 cases and 531 controls were from Guangzhou Women and Children's Medical Center and the rest were from The First Affiliated Hospital of Zhengzhou University 25, 43, 44. All the participants were unrelated Chinese Han children. Written informed consent was provided before the study by all participants or their guardians. The study protocols obtained approval from the Institutional Review Board of Guangzhou Women and Children's Medical Center and the Institutional Review Board of The First Affiliated Hospital of Zhengzhou University. SNP selection and genotyping We chose potentially functional polymorphisms of XPA gene from dbSNP database (http://www.ncbi.nlm.nih.gov/) and an online tool, SNPinfo (http:// snpinfo.niehs.nih.gov/) using the selection criteria described in our published studies 45. Two SNPs (rs1800975 T>C, and rs3176752 G>T) in the XPA gene were selected in the final analysis. In them, rs1800975 T>C might affect transcription activity, while rs3176752 G>T might affect the microRNA binding site activity. Genomic DNA was extracted from peripheral blood donated by all the included subjects using a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China). TaqMan real-time PCR was performed to genotype the selected SNPs. The details of genotyping protocol could be obtained in previous studies 46-49. As a quality control, 10% of the random samples were carried out twice. A concordance rate of 100% was got for all duplicate sets. Statistical analysis First, deviation from Hardy-Weinberg equilibrium (HWE) of the selected SNPs among controls was assessed by goodness-of-fit χ2 test. Two-sided chi-squared test was used to identify the difference of the demographic variables and allele frequencies between the cases and controls. Logistic regression analysis, served to provide odds ratios (ORs) and 95% confidence intervals (CIs), was adopted to estimate the association between XPA SNPs and neuroblastoma risk. Significance was achieved when P values were less than 0.05. All statistical analyses were performed using the version 9.4 SAS statistical package (SAS Institute, Cary, NC). Results Correlation of XPA gene polymorphisms with neuroblastoma susceptibility The detailed characteristics of all the cases and controls could be found in our previously published articles 40-42. In brief, no statistically significant differences were found between cases and controls regarding age (P>0.05) and gender (P>0.05). According to the INSS criteria, 69 (17.56%), 93 (23.66%), 68 (17.30%), 143 (36.39%), and 11 (2.80%) patients were diagnosed with clinical stages I, II, III, IV, and 4s disease, respectively. In terms of tumor sites, 153 (38.93%) neuroblastomas occurred in the adrenal glands, 109 (27.74%) in the mediastinum, 87 (22.14%) in retroperitoneal regions, and 36 (9.16%) in other regions. To evaluate the relationship between these two SNPs as well as the combined risk genotypes of XPA gene (rs1800975 T>C, rs3176752 G>T) and risk of neuroblastoma, crude and adjusted ORs and their 95% CIs were calculated. The main results of the above calculations were listed in Table 1. In general, we failed to detect any statistically significant differences in the genotype frequencies distribution of rs1800975 T>C or rs3176752 G>T polymorphism. Moreover, none of the two polymorphisms were significantly associated with neuroblastoma risk. The allele frequencies for controls in both rs1800975 and rs3176752 genotypes were in Hardy-Weinberg equilibrium, with P values equal to 0.068 and 0.416, respectively. Further analysis of the combined effect of risk genotypes revealed that 1-2 combined risk genotypes was markedly associated with an increased risk of neuroblastoma, compared with those without any risk genotypes (adjusted OR=1.28; 95% CI=1.001-1.64, P=0.049). Stratification analysis of XPA gene polymorphisms with neuroblastoma susceptibility We further conducted subgroup analyses by age, gender, tumor sites of origin and clinical stages to evaluate the contributions of the selected polymorphisms and their combined risk genotypes to the risk of neuroblastoma (Table 2). However, the calculated results indicated that there lacks significant difference association between the selected polymorphisms as well as their combined risk genotypes and neuroblastoma risk under any of the evaluated subgroups. Haplotype analysis As shown in Table 3, we did not find any haplotype can influence neuroblastoma susceptibility significantly. Discussion In order to identify the association between XPA SNPs and neuroblastoma risk, we conducted a two-center case-control study by recruiting 393 neuroblastoma patients and 812 healthy control subjects from Chinese population. Our results indicated that variations in XPA gene had no significant association with neuroblastoma risk. To the best of our knowledge, this is the first study investigating the associations in Chinese children. XPA gene is mapped to chromosome 9p22.3. It encodes a relatively small 273-residue protein without enzymatic activity. Alternatively, XPA functions as a scaffold by interacting with many other NER proteins such as replication protein A, transcription factor IIH and excision repair cross complementing group 1-xeroderma pigmentosum group F protein complex 50. Through interacting with these proteins, XPA protein facilitates the formation of the assembly and structural organization of human NER incision complexes 51. Current evidence indicates that mutations in XPA gene impairs normal function of NER 51. Thus, it is biologically reasonable that functional XPA gene variants may influence the DNA repair capacity, and thereby modify cancer risk. A vast number of studies has been performed to investigate the association of XPA gene SNPs with cancer risk. For example, the rs1800975 T>C polymerphism of XPA gene has been reported to be associated with increased risk of colorectal cancer in a study conducted in Poland 36. Another study conducted in Norway indicated that XPA gene rs1800975 T>C was associated with a significant reduction in the risk of lung cancer 52. The discrepancy results suggested that the same polymorphism might have different roles in cancer susceptibility depending on cancer sites and ethnicities, not to mention the different polymorphisms in candidate gene. Herein, for the first time we explored whether XPA gene SNPs could affect neuroblastoma susceptibility in Chinese children. Unexpectedly, neither of the two polymorphisms of XPA gene was associated with neuroblastoma risk, in the overall analysis and stratified analysis. The null association might be partially attributed to the limited statistical power caused by relatively small sample size. Moreover, the low-penetrance of single polymorphism might also account for such a null association. Neuroblastoma is a multifactorial and complex disease resulting from interplay between multiple genetic and environmental factors 1, 5, 53. Previous study has demonstrated that polymorphisms in individual genes might not have enough impact on the risk of cancer 54. Thus, it would be expected that the combined SNPs might have greater effects. Indeed, combined analysis revealed that 1-2 combined risk genotypes was markedly associated with an increased risk of neuroblastoma, compared with 0 risk genotypes. Consistent with our results, Tse et al. 55, found that compared with one variant allele alone, the combined four NER SNPs could significantly increase risk of esophageal adenocarcinoma. Similar variant-dosage effect was also observed in our former case-control study in other NER genes 56. Although this study has its own merits, limitation accompanies. First, as a hospital-based case-control study, selection bias is inevitable. Second, the sample size of this case-control study is relatively small, especially for the stratification analysis. As a result, the statistical power was compromised. Thus, these findings call for replication studies in larger sample size. Third, the number of the analyzed SNPs is limited. Fourth, neuroblastoma is a heterogeneous disease with complex etiology; thus, genetic analysis alone is far more enough to elucidate its etiology. Yet due to the nature of retrospective investigations, we failed to obtain other risk exposing factors, such as paternal exposures, living environment, and dietary intake. Further studies including environmental factors analysis and gene-environment interaction analysis are warranted. Fifth, the conclusion obtained from this study could not be directly extrapolated to other ethnicities, as all the included subjects were restricted to unrelated Chinese Han ethnicity. In summary, we first investigated the association of XPA gene polymorphisms with neuroblastoma risk. Our results indicated that no single XPA gene polymorphism could influence neuroblastoma risk. Ongoing epidemiological studies with larger samples from different ethnicities are needed to further elucidate the role of XPA gene polymorphisms in neuroblastoma tumorigenesis. This work was supported by grants from National Natural Science Foundation of China (No: 81502187), and Pearl River S&T Nova Program of Guangzhou (No: 201710010086). Abbreviations GWASgenome-wide association study SNPsingle nucleotide polymorphism NERnucleotide excision repair XPAxeroderma pigmentosum complementary group A, HWE, Hardy-Weinberg equilibrium ORodds ratio CIconfidence interval. Table 1 Logistic regression analysis for the association between XPA gene polymorphisms and neuroblastoma susceptibility Genotype Cases (N=393) Controls (N=812) P a Crude OR (95% CI) P Adjusted OR (95% CI) b P b rs1800975 (HWE=0.068) TT 111 (28.24) 191 (23.52) 1.00 1.00 TC 197 (50.13) 432 (53.20) 0.79 (0.59-1.05) 0.099 0.79 (0.59-1.05) 0.101 CC 85 (21.63) 189 (23.28) 0.77 (0.55-1.10) 0.147 0.78 (0.55-1.10) 0.150 Additive 0.207 0.88 (0.74-1.04) 0.134 0.88 (0.74-1.04) 0.137 Dominant 282 (71.76) 621 (76.48) 0.076 0.78 (0.60-1.03) 0.077 0.78 (0.60-1.03) 0.079 Recessive 308 (78.37) 623 (76.72) 0.522 0.91 (0.68-1.22) 0.523 0.91 (0.68-1.22) 0.527 rs3176752 (HWE=0.416) GG 301 (76.59) 639 (78.69) 1.00 1.00 GT 83 (21.12) 160 (19.70) 1.10 (0.82-1.48) 0.526 1.10 (0.82-1.49) 0.516 TT 9 (2.29) 13 (1.60) 1.47 (0.62-3.48) 0.381 1.47 (0.62-3.48) 0.382 Additive 0.576 1.13 (0.88-1.46) 0.331 1.14 (0.88-1.47) 0.325 Dominant 92 (23.41) 173 (21.31) 0.408 1.13 (0.85-1.51) 0.409 1.13 (0.85-1.51) 0.400 Recessive 384 (97.71) 799 (98.40) 0.402 1.44 (0.61-3.40) 0.405 1.44 (0.61-3.40) 0.407 Combine risk genotypes c 0 d 232 (59.03) 527 (64.90) 0.132 1.00 1.00 1 d 119 (30.28) 206 (25.37) 1.31 (1.00-1.73) 0.052 1.31 (1.00-1.72) 0.054 2 d 42 (10.69) 79 (9.73) 1.21 (0.81-1.81) 0.361 1.21 (0.81-1.82) 0.354 0 232 (59.03) 527 (64.90) 1.00 1.00 1-2 161 (40.97) 285 (35.10) 0.048 1.28 (1.002-1.64) 0.048 1.28 (1.001-1.64) 0.049 a χ2 test for genotype distributions between neuroblastoma cases and controls. b Adjusted for age and gender. c Risk genotypes were rs1800975 TT, and rs3176752 GT/TT. d 0 was no risk genotype, 1 was rs1800975 TT or rs3176752 GT/TT, 2 was rs1800975 TT and rs3176752 GT/TT. Table 2 Stratification analysis of XPA gene polymorphisms with neuroblastoma susceptibility Variables rs1800975 (cases/controls) Adjusted OR a P a rs3176752 (cases/controls) Adjusted OR a P a Risk genotypes (cases/controls) Adjusted OR a P a TT TC/CC (95% CI) GG GT/TT (95% CI) 0-1 2 (95% CI) Age, month ≤18 31/64 95/241 0.81 (0.50-1.33) 0.411 93/240 33/65 1.31 (0.81-2.12) 0.273 78/203 48/102 1.23 (0.80-1.89) 0.357 >18 80/127 187/380 0.78 (0.56-1.08) 0.133 208/399 59/108 1.05 (0.73-1.51) 0.782 154/324 113/183 1.31 (0.96-1.77) 0.085 Gender Females 43/74 125/268 0.81 (0.52-1.24) 0.324 133/268 35/74 0.94 (0.60-1.48) 0.798 104/226 64/116 1.19 (0.81-1.75) 0.364 Males 68/117 157/353 0.78 (0.55-1.11) 0.169 168/371 57/99 1.27 (0.87-1.84) 0.213 128/301 97/169 1.33 (0.96-1.84) 0.086 Sites of origin Adrenal gland 43/191 110/621 0.80 (0.54-1.19) 0.269 119/639 34/173 1.06 (0.70-1.61) 0.777 88/527 65/285 1.35 (0.95-1.92) 0.096 Retroperitoneal 24/191 63/621 0.80 (0.49-1.33) 0.392 68/639 19/173 1.02 (0.60-1.75) 0.931 53/527 34/285 1.19 (0.75-1.87) 0.461 Mediastinum 32/191 77/621 0.73 (0.47-1.13) 0.158 80/639 29/173 1.33 (0.84-2.10) 0.226 63/527 46/285 1.36 (0.91-2.05) 0.138 Others 10/191 26/621 0.79 (0.37-1.66) 0.528 27/639 9/173 1.22 (0.56-2.65) 0.613 22/527 14/285 1.19 (0.60-2.36) 0.624 Clinical stages I+II+4s 44/191 118/621 0.81 (0.55-1.19) 0.297 119/639 43/173 1.33 (0.90-1.96) 0.150 95/527 67/285 1.32 (0.93-1.86) 0.115 III+IV 64/191 147/621 0.72 (0.51-1.01) 0.055 167/639 44/173 0.98 (0.68-1.43) 0.929 123/527 88/285 1.31 (0.96-1.79) 0.089 a Adjusted for age and gender without the corresponding stratification factor. Table 3 Association between inferred haplotypes of XPA gene and neuroblastoma susceptibility Haplotypes a Cases (N=786) Controls (N=1624) Crude OR (95% CI) P Adjusted OR b (95% CI) P b CG 317 (40.33) 716 (44.09) 1.00 1.00 CT 50 (6.36) 94 (5.79) 1.20 (0.83-1.74) 0.328 1.20 (0.83-1.74) 0.328 TG 368 (46.82) 722 (44.46) 1.15 (0.96-1.38) 0.130 1.15 (0.96-1.38) 0.134 TT 51 (6.49) 92 (5.67) 1.25 (0.87-1.81) 0.230 1.26 (0.87-1.81) 0.226 a The haplotypes order were rs1800975 and rs3176752. b Obtained in logistic regression models with adjustment for age and gender. ==== Refs 1 Matthay KK Maris JM Schleiermacher G Nakagawara A Mackall CL Diller L Neuroblastoma Nat Rev Dis Primers 2016 2 16078 27830764 2 Cheung NK Dyer MA Neuroblastoma: developmental biology, cancer genomics and immunotherapy Nat Rev Cancer 2013 13 397 411 23702928 3 Bao PP Li K Wu CX Huang ZZ Wang CF Xiang YM [Recent incidences and trends of childhood malignant solid tumors in Shanghai, 2002-2010] Zhonghua Er Ke Za Zhi 2013 51 288 94 23927803 4 Gurney JG Ross JA Wall DA Bleyer WA Severson RK Robison LL Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992 J Pediatr Hematol Oncol 1997 19 428 32 9329464 5 Maris JM Hogarty MD Bagatell R Cohn SL Neuroblastoma Lancet 2007 369 2106 20 17586306 6 Shimada H Ambros IM Dehner LP Hata J Joshi VV Roald B The International Neuroblastoma Pathology Classification (the Shimada system) Cancer 1999 86 364 72 10421273 7 Maris JM Recent advances in neuroblastoma N Engl J Med 2010 362 2202 11 20558371 8 Esposito MR Aveic S Seydel A Tonini GP Neuroblastoma treatment in the post-genomic era J Biomed Sci 2017 24 14 28178969 9 Mosse YP Laudenslager M Longo L Cole KA Wood A Attiyeh EF Identification of ALK as a major familial neuroblastoma predisposition gene Nature 2008 455 930 5 18724359 10 Chen Y Takita J Choi YL Kato M Ohira M Sanada M Oncogenic mutations of ALK kinase in neuroblastoma Nature 2008 455 971 4 18923524 11 Bourdeaut F Trochet D Janoueix-Lerosey I Ribeiro A Deville A Coz C Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma Cancer Lett 2005 228 51 8 15949893 12 Mosse YP Laudenslager M Khazi D Carlisle AJ Winter CL Rappaport E Germline PHOX2B mutation in hereditary neuroblastoma Am J Hum Genet 2004 75 727 30 15338462 13 Devoto M Specchia C Laudenslager M Longo L Hakonarson H Maris J Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma Hum Hered 2011 71 135 9 21734404 14 Cook MN Olshan AF Guess HA Savitz DA Poole C Blatt J Maternal medication use and neuroblastoma in offspring Am J Epidemiol 2004 159 721 31 15051581 15 Menegaux F Olshan AF Neglia JP Pollock BH Bondy ML Day care, childhood infections, and risk of neuroblastoma Am J Epidemiol 2004 159 843 51 15105177 16 Maris JM Mosse YP Bradfield JP Hou C Monni S Scott RH Chromosome 6p22 locus associated with clinically aggressive neuroblastoma N Engl J Med 2008 358 2585 93 18463370 17 Capasso M Devoto M Hou C Asgharzadeh S Glessner JT Attiyeh EF Common variations in BARD1 influence susceptibility to high-risk neuroblastoma Nat Genet 2009 41 718 23 19412175 18 Wang K Diskin SJ Zhang H Attiyeh EF Winter C Hou C Integrative genomics identifies LMO1 as a neuroblastoma oncogene Nature 2011 469 216 20 21124317 19 Nguyen le B Diskin SJ Capasso M Wang K Diamond MA Glessner J Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci PLoS Genet 2011 7 e1002026 21436895 20 Diskin SJ Capasso M Schnepp RW Cole KA Attiyeh EF Hou C Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma Nat Genet 2012 44 1126 30 22941191 21 Diskin SJ Capasso M Diamond M Oldridge DA Conkrite K Bosse KR Rare variants in TP53 and susceptibility to neuroblastoma J Natl Cancer Inst 2014 106 dju047 24634504 22 He J Zhong W Zeng J Zhu J Zhang R Wang F LMO1 gene polymorphisms contribute to decreased neuroblastoma susceptibility in a Southern Chinese population Oncotarget 2016 7 22770 8 27009839 23 He J Yang T Zhang R Zhu J Wang F Zou Y Potentially functional polymorphisms in the LIN28B gene contribute to neuroblastoma susceptibility in Chinese children J Cell Mol Med 2016 20 1534 41 27021521 24 Zhang R Zou Y Zhu J Zeng X Yang T Wang F The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population Int J Med Sci 2016 13 133 8 26941572 25 Zhang J Lin H Wang J He J Zhang D Qin P LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study Oncotarget 2017 8 65620 6 29029458 26 He J Wang F Zhu J Zhang Z Zou Y Zhang R The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children Aging (Albany NY) 2017 9 852 9 28275206 27 Stadler ZK Thom P Robson ME Weitzel JN Kauff ND Hurley KE Genome-wide association studies of cancer J Clin Oncol 2010 28 4255 67 20585100 28 Wood RD Mitchell M Sgouros J Lindahl T Human DNA repair genes Science 2001 291 1284 9 11181991 29 Gillet LC Scharer OD Molecular mechanisms of mammalian global genome nucleotide excision repair Chem Rev 2006 106 253 76 16464005 30 Berwick M Vineis P Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review J Natl Cancer Inst 2000 92 874 97 10841823 31 Friedberg EC How nucleotide excision repair protects against cancer Nat Rev Cancer 2001 1 22 33 11900249 32 Christmann M Tomicic MT Roos WP Kaina B Mechanisms of human DNA repair: an update Toxicology 2003 193 3 34 14599765 33 Cleaver JE Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum J Dermatol Sci 2000 23 1 11 10699759 34 Sugitani N Shell SM Soss SE Chazin WJ Redefining the DNA-binding domain of human XPA J Am Chem Soc 2014 136 10830 3 25056193 35 Scharer OD Nucleotide excision repair in eukaryotes Cold Spring Harb Perspect Biol 2013 5 a012609 24086042 36 Dziki L Dziki A Mik M Majsterek I Kabzinski J Modulation of Colorectal Cancer Risk by Polymorphisms in 51Gln/His, 64Ile/Val, and 148Asp/Glu of APEX Gene; 23Gly/Ala of XPA Gene; and 689Ser/Arg of ERCC4 Gene Gastroenterol Res Pract 2017 2017 3840243 28386271 37 Lu B Li J Gao Q Yu W Yang Q Li X Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA Gene 2014 542 64 8 24582975 38 Mei C Hou M Guo S Hua F Zheng D Xu F Polymorphisms in DNA repair genes of XRCC1, XPA, XPC, XPD and associations with lung cancer risk in Chinese people Thorac Cancer 2014 5 232 42 26767006 39 Ruiz-Cosano J Torres-Moreno D Conesa-Zamora P Influence of polymorphisms in ERCC5, XPA and MTR DNA repair and synthesis genes in B-cell lymphoma risk. A case-control study in Spanish population J BUON 2013 18 486 90 23818366 40 He J Zou Y Liu X Zhu J Zhang J Zhang R Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children Mol Ther Nucleic Acids 2018 11 1 8 29858046 41 Zhang Z Chang Y Jia W Zhang J Zhang R Zhu J LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population Biosci Rep 2018 38 BSR20171667 29339420 42 Zhuo ZJ Liu W Zhang J Zhu J Zhang R Tang J Functional Polymorphisms at ERCC1/XPF Genes Confer Neuroblastoma Risk in Chinese Children EBioMedicine 2018 30 113 9 29544698 43 Zhang J Zhuo ZJ Wang J He J Yang L Zhang D CASC15 gene polymorphisms reduce neuroblastoma risk in Chinese children Oncotarget 2017 8 91343 9 29207648 44 Wu Q Zhuo ZJ Zeng J Zhang J Zhu J Zou Y Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study J Cancer 2018 9 535 9 29483959 45 He J Qiu LX Wang MY Hua RX Zhang RX Yu HP Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations Hum Genet 2012 131 1235 44 22371296 46 Li J Zou L Zhou Y Li L Zhu Y Yang Y A low-frequency variant in SMAD7 modulates TGF-beta signaling and confers risk for colorectal cancer in Chinese population Mol Carcinog 2017 56 1798 807 28218435 47 Lou J Gong J Ke J Tian J Zhang Y Li J A functional polymorphism located at transcription factor binding sites, rs6695837 near LAMC1 gene, confers risk of colorectal cancer in Chinese populations Carcinogenesis 2017 38 177 83 28039327 48 Gong J Tian J Lou J Wang X Ke J Li J A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267 Ann Oncol 2018 29 632 9 29267898 49 Zou D Lou J Ke J Mei S Li J Gong Y Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression Eur J Cancer 2018 93 1 9 29428571 50 Ikegami T Kuraoka I Saijo M Kodo N Kyogoku Y Morikawa K Solution structure of the DNA- and RPA-binding domain of the human repair factor XPA Nat Struct Biol 1998 5 701 6 9699634 51 States JC McDuffie ER Myrand SP McDowell M Cleaver JE Distribution of mutations in the human xeroderma pigmentosum group A gene and their relationships to the functional regions of the DNA damage recognition protein Hum Mutat 1998 12 103 13 9671271 52 Zienolddiny S Campa D Lind H Ryberg D Skaug V Stangeland L Polymorphisms of DNA repair genes and risk of non-small cell lung cancer Carcinogenesis 2006 27 560 7 16195237 53 Capasso M Diskin SJ Genetics and genomics of neuroblastoma Cancer Treat Res 2010 155 65 84 20517688 54 Pan J Lin J Izzo JG Liu Y Xing J Huang M Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway Carcinogenesis 2009 30 785 92 19270000 55 Tse D Zhai R Zhou W Heist RS Asomaning K Su L Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk Cancer Causes Control 2008 19 1077 83 18478337 56 He J Wang F Zhu J Zhang R Yang T Zou Y Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population J Cell Mol Med 2016 20 1481 90 27019310